Latest news with #www.tmxmoney.com
Yahoo
30-04-2025
- Business
- Yahoo
BioSyent to Present at 2025 Bloom Burton & Co. Healthcare Investor Conference
MISSISSAUGA, Ontario, April 30, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. ('BioSyent', TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2025 Bloom Burton & Co. Healthcare Investor Conference. The conference will be held in Toronto at the Metro Toronto Convention Centre (North Building) on Monday, May 5th and Tuesday, May 6th, 2025. Mr. René Goehrum, President and CEO of BioSyent, will present to investors an overview of BioSyent's business and corporate activities on Monday, May 5th at 11:30am EDT. Mr. Goehrum will also be available to meet with investors on a one-on-one basis during the conference. These one-on-one meetings can be requested by registered attendees through the conference portal online: About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol 'RX', BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty, and international business units. As of the date of this press release, the Company has 11,254,638 common shares outstanding. For a direct market quote for the TSX Venture Exchange and other Company financial information please visit For further information please contact: Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: investors@ 905-206-0013Web: This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Yahoo
06-03-2025
- Business
- Yahoo
BioSyent Schedules Fourth Quarter and Full Year 2024 Earnings Release for March 13, 2025
MISSISSAUGA, Ontario, March 06, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. ('BioSyent', 'the Company', TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2024 on Thursday, March 13, 2025 after market hours. A presentation on the Company's fourth quarter and full year 2024 results by René Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol 'RX', BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units. As of the date of this press release, the Company has 11,264,517 common shares outstanding. For a direct market quote for the TSX Venture Exchange and other Company financial information please visit For further information please contact: Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: investors@ 905-206-0013Web: This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press in to access your portfolio
Yahoo
06-03-2025
- Business
- Yahoo
BioSyent Schedules Fourth Quarter and Full Year 2024 Earnings Release for March 13, 2025
MISSISSAUGA, Ontario, March 06, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. ('BioSyent', 'the Company', TSX Venture: RX) will be reporting its financial results for the three months and full year ended December 31, 2024 on Thursday, March 13, 2025 after market hours. A presentation on the Company's fourth quarter and full year 2024 results by René Goehrum, BioSyent President and CEO, will also be available on the Company's website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol 'RX', BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units. As of the date of this press release, the Company has 11,264,517 common shares outstanding. For a direct market quote for the TSX Venture Exchange and other Company financial information please visit For further information please contact: Mr. René C. GoehrumPresident and CEOBioSyent Inc.E-Mail: investors@ 905-206-0013Web: This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press in to access your portfolio
